Department of Clinical Pharmacology and Medicine, College of Medicine, Al-Mustansiriya University, Baghdad, Iraq.
Department of Biotechnology, College of Sciences, Taif University, P.O. Box 11099, Taif, 21944, Saudi Arabia.
Naunyn Schmiedebergs Arch Pharmacol. 2022 Dec;395(12):1463-1475. doi: 10.1007/s00210-022-02284-6. Epub 2022 Sep 5.
Coronavirus disease 2019 (COVID-19) is a current pandemic disease caused by a novel severe acute respiratory syndrome coronavirus virus respiratory type 2 (SARS-CoV-2). SARS-CoV-2 infection is linked with various neurological manifestations due to cytokine-induced disruption of the blood brain barrier (BBB), neuroinflammation, and peripheral neuronal injury, or due to direct SARS-CoV-2 neurotropism. Of note, many repurposed agents were included in different therapeutic protocols in the management of COVID-19. These agents did not produce an effective therapeutic eradication of SARS-CoV-2, and continuing searching for novel anti-SARS-CoV-2 agents is a type of challenge nowadays. Therefore, this study aimed to review the potential anti-inflammatory and antioxidant effects of citicoline in the management of COVID-19.
新型冠状病毒病（COVID-19）是由新型严重急性呼吸系统综合征冠状病毒 2 型（SARS-CoV-2）引起的当前大流行疾病。由于细胞因子引起的血脑屏障（BBB）破坏、神经炎症和周围神经元损伤，或由于 SARS-CoV-2 的直接嗜神经性，SARS-CoV-2 感染与各种神经系统表现有关。值得注意的是，许多已重新定位的药物被纳入 COVID-19 管理的不同治疗方案中。这些药物并没有有效地清除 SARS-CoV-2，因此，目前仍在继续寻找新型抗 SARS-CoV-2 药物，这是一种挑战。因此，本研究旨在综述胞磷胆碱在 COVID-19 管理中的潜在抗炎和抗氧化作用。
